{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.5","upperLimit":"13.1","value":"9.6"},{"groupId":"OG001","lowerLimit":"6.7","upperLimit":"16.8","value":"10.4"},{"groupId":"OG002","lowerLimit":"2","upperLimit":"17.17","value":"10.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"description":"To evaluate the time to next treatment achieved with physician's choice selinexor-based combination therapy","dispersionType":"95% Confidence Interval","groups":[{"description":"Group 1:\n\n* Selinexor 60 mg PO days 1, 8, 15\n* Pomalidomide 4 mg PO on days 1-21\n* Dexamethasone 40 mg PO or IV on days 1, 8, 15, 22\n* 28 day treatment cycles\n\nSelinexor: Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).\n\nPomalidomide: Oral Table\n\nDexamethasone: Oral tablet or injection","id":"OG000","title":"Group 1"},{"description":"Group 2:\n\nSelinexor 80 mg PO days 1, 8, 15 Daratumumab 1,800mg/30,000 units subcutaneous injection on days 1, 8, 15, 22 of cycles 1 and 2, days 1, 15 of cycles 3-6, day 1 of cycles \\>6 Dexamethasone 40 mg PO or IV days 1, 8, 15, 22 28 day treatment cycle Selinexor: Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).\n\nDaratumumab: Injection Dexamethasone: Oral tablet or injection","id":"OG001","title":"Group 2"},{"description":"Group 3:\n\n* Selinexor 80 mg PO days 1, 8, 15\n* Carfilzomib IV infusion 20 mg/m2 cycle 1, day 1, 56 mg/m2 cycle 1 day 8, 15. Cycle 2+ days 1, 8, 15.\n* Dexamethasone 40 mg IV or PO days 1, 8, 15, 22\n* 28 day treatment cycle\n\nSelinexor: Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).\n\nCarfilzomib: Injection\n\nDexamethasone: Oral tablet or injection","id":"OG002","title":"Group 3"}],"paramType":"MEDIAN","populationDescription":"The study sample size was powered to analyze the total group of patients enrolled. It was not powered to analyze each treatment regimen individually.","reportingStatus":"POSTED","timeFrame":"End of Treatment +2 years, or date of progression (whichever comes first), assessed up to 2 years","title":"Time to Next Treatment","type":"SECONDARY","unitOfMeasure":"Months"}